Tag: immunology

  • Spotlight- Ikechukwu Ofuani: A Master of Government Relations, Public Policy & Public-Private Partnerships

    Spotlight- Ikechukwu Ofuani: A Master of Government Relations, Public Policy & Public-Private Partnerships

    Ikechukwu Sylvester Ofuani, LLB, BL, MPA, DPO (Ghana), is a distinguished lawyer, government affairs strategist, and public policy leader whose career spans more than 18 years across Africa, the United Kingdom, and Ireland. Renowned for his expertise in government relations, regulatory affairs, stakeholder engagement, and policy advocacy, he has built a reputation as one of the leading voices shaping the intersection of public policy, corporate strategy, and development across Sub-Saharan Africa.

    With professional experience cutting across healthcare, MedTech, FMCG, international trade, development, corporate communications, and public-private partnerships, Ikechukwu has consistently demonstrated the ability to navigate complex regulatory environments while fostering strategic collaboration between governments, private institutions, multilateral organisations, and civil society stakeholders.

    Over the years, he has held senior leadership roles at organisations including Policy Vault Africa, Johnson & Johnson, Procter & Gamble, and the National Identity Management Commission project. In these capacities, he has led high-level engagements with governments, regulators, trade associations, development institutions, and international stakeholders, helping organisations shape policy ecosystems, strengthen institutional relationships, and drive sustainable impact.

    A significant part of his professional journey was spent at Johnson & Johnson, where he served as Director of Government Affairs and Policy for West and Central Africa. In that role, he led health system strengthening strategies and coordinated complex partnerships involving governments, donor agencies, regulatory institutions, and healthcare stakeholders across the region. His work focused on policy reform, regulatory harmonisation, strategic communications, grants management, and advocacy initiatives designed to strengthen healthcare delivery systems.

    Ikechukwu also played a strategic role in regional health diplomacy and pandemic preparedness. As one of Johnson & Johnson’s focal persons for African Union engagements on Ebola vaccines and pandemic preparedness, he coordinated engagements involving access teams, regulatory experts, medical affairs specialists, and global public health stakeholders. During the COVID-19 pandemic, he supported vaccine deployment efforts in Nigeria, Ghana, and Cameroon, and contributed to initiatives to address vaccine hesitancy and improve uptake across African countries.

    His contributions to Africa’s healthcare policy ecosystem have attracted continental recognition. He has publicly represented Johnson & Johnson as Director of Worldwide Government Affairs and Policy for West and Central Africa and has participated in high-level conversations on strengthening health regulatory systems, including at the U.S.-Africa Business Summit.

    Beyond multinational corporate leadership, Ikechukwu has also distinguished himself in the advisory and policy consulting space. He currently co-leads PV Advisors and Policy Vault Africa, a policy and government affairs advisory platform that supports organisations navigating Africa’s complex regulatory and stakeholder landscape. Through the platform, he provides strategic guidance to clients across sectors, helping them engage effectively with governments, regulators, policymakers, and development institutions.

    Under his leadership, Policy Vault Africa has contributed to broader governance and institutional reform conversations across the continent. One notable example is the organisation’s engagement with Nigeria’s Ministry of Budget and National Planning on policy digitisation and the preservation of institutional memory. The initiative seeks to improve transparency, accessibility, and the preservation of authentic policy documents for governments, researchers, private-sector actors, and citizens. Ikechukwu has consistently advocated the importance of accessible and credible policy information as a foundation for informed decision-making and long-term development planning.

    Another defining area of his impact has been public health advocacy and child survival initiatives. Ikechukwu currently serves as Project Lead of the SARMAAN Advocacy Team, where he is helping reposition SARMAAN II from a donor-supported intervention into a nationally owned and sustainably financed public health priority. Through strategic advocacy, communications, stakeholder engagement, and sustainability planning, he is supporting efforts to integrate child survival interventions into Nigeria’s broader healthcare policy architecture. His work places strong emphasis on domestic financing, institutional ownership, and building trust among governments, implementing partners, and local communities.

    His ability to transform policy conversations into measurable outcomes is further evident in his work on health system-strengthening partnerships. While at Johnson & Johnson, he successfully secured a ₦300 million healthcare partnership with Kebbi State focused on improving healthcare infrastructure across oncology, mental health, and immunology. The initiative reportedly led to the identification and treatment of over 200 indigent patients and became a model replicated in additional states.

    Prior to his healthcare and advisory engagements, Ikechukwu also recorded significant achievements in trade facilitation and investment enablement during his time at Procter & Gamble Nigeria. There, he led strategic engagements with regulatory agencies and government institutions across West Africa, facilitating multimillion-dollar investment approvals, securing customs fast-track arrangements, and supporting major industrial projects. Among his notable contributions was the coordination of government-facing engagements surrounding the commissioning of a US$300 million diaper manufacturing plant in Agbara, Ogun State, attended by senior government officials including the Vice President of Nigeria.

    Beyond his corporate and policy engagements, Ikechukwu is also committed to social impact and advocacy. He currently sits on the board of Stockport Advocacy in the United Kingdom, an organisation focused on advocating for children with learning disabilities. His leadership and contributions to public-private partnerships and Africa-focused policy engagement have earned him recognition, including being named a 2024 GCC Powerlist awardee.

    What distinguishes Ikechukwu Sylvester Ofuani is his rare combination of legal training, policy expertise, stakeholder intelligence, and strategic leadership. Across multinational corporations, advisory platforms, donor-supported programmes, and government-facing initiatives, he has built a career centred on helping institutions navigate complexity, build trust with governments, and translate policy engagement into tangible social and commercial impact.

    His journey reflects the growing importance of strategic government relations and policy leadership in shaping Africa’s development trajectory. Through his work, Ikechukwu continues to demonstrate that effective engagement between the public and private sectors remains one of the most powerful tools for driving sustainable growth, institutional reform, and transformational impact across the continent.

  • Roche launches the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics

    Roche launches the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics

    …the Roche Digital Pathology solution helps empower the digital transformation of pathology and enable better, more personalised healthcare

    Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced the CE launch of the next-generation VENTANA DP 600 slide scanner (CE-IVD marked). This high-capacity slide scanner produces excellent image quality of stained histology slides from patient tissue samples, while providing ease of use and workflow flexibility for the pathology lab.

    “The VENTANA DP 600 slide scanner is vital for the advancement of healthcare in Africa. This solution helps to ensure that each patient receives the most effective treatment plan possible, regardless of where they live,” said Alan Yates Ad-Interim General Manager of Roche Diagnostics. He added, “When combined with our innovative AI image analysis algorithms, the VENTANA DP 600 creates opportunities for better collaboration and remote diagnosis, which can be lifesaving in African countries with large rural populations. Innovative solutions such as this allow us to move closer to our vision of enabling health for every African.”

    The VENTANA DP 600 slide scanner is an important addition to the Roche Digital Pathology portfolio, which provides innovative, high-quality digital solutions that automate tissue diagnostics and empower pathologists to provide faster and more comprehensive diagnostic results to healthcare providers and their patients2.

    Digital Pathology refers to the digitalisation of the traditional pathology workflow starting from slide scanning to visualisation to analysis. Digital Pathology is transforming traditional histopathology by improving efficiency, depth of analysis, and opportunity for collaboration in pathology workflows.

    For example, once the slide scanner captures and converts stained tissue on glass slides to digital images, these images can be managed, shared, and analysed by pathologists and can help determine a cancer patient’s treatment. 

    This new 240-slide scanner, which builds on the success of the 6-slide VENTANA DP 200 scanner, will help anatomic pathology laboratories accelerate the digitalisation of their pathology workflow. Both scanners feature the same innovative optics and dynamic focus technology for high-resolution, high-quality colour images that accurately reproduce the image quality that pathologists see under microscopes.

    About Roche Digital Pathology

    Built by pathologists, for pathologists, the end-to-end Roche Digital Pathology solution focuses on maximising the pathologists’ unique training, skills, and vision. The Roche Digital Pathology solution is an integrated solution that combines innovative slide scanners, patient-centric pathology workflow software and image analysis algorithms, working in integrated harmony with the full Roche tissue diagnostics portfolio.

    The newest addition to the Roche Digital Pathology portfolio is the 240-slide, high-capacity brightfield VENTANA DP 600 slide scanner that offers workflow flexibility to suit a variety of anatomical pathology labs. 

    VENTANA slide scanners use tray-based systems engineered with minimal moving parts. The slides move through the system on the tray without interference by a robotic mechanism, allowing for a high-quality scan even if the slides are wet, frozen, or if cover slips are slightly off centre. The tray-based system eliminates slide-handling errors such as breakage and loss of slides2.

    About Roche
    Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.

    Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

    Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

    The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.